Telehealth Goes Vertical on Peptides: Noom Acquires Tailor Made Compounding, Hims & Hers Expands Production, and Eloralintide's Combination Era Begins — June 11, 2026
Table of Contents
Telehealth's Vertical Integration Race Into Peptides
With the FDA's Pharmacy Compounding Advisory Committee (PCAC) vote on BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP now just six weeks away (July 23–24, 2026), the most telling industry signal this week didn't come from a drugmaker — it came from consumer telehealth. Noom has finalized its acquisition of Tailor Made Compounding (TMC), a licensed 503A compounding pharmacy operating in 46 states including California. The stated goal: expand beyond weight management into 'prescription-grade wellness,' with peptide therapies such as sermorelin and healthy-aging interventions like NAD+ joining the formulary. Noom now joins Hims & Hers — which acquired a California-based peptide production facility in February 2025 — along with Hone Health, Gameday Men's Health, and 1st Optimal in positioning to make peptide prescriptions as friction-free as a GLP-1 refill. Two of the largest consumer health platforms in the U.S. now own their own 503A peptide manufacturing capability before the first compounding green light has even been voted on.
Why Owning a 503A Pharmacy Matters Now
The April 2026 removal of 12 peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, LL-37, Dihexa, GHK-Cu, PEG-MGF, Melanotan II) from FDA Category 2 restored a potential regulated pathway, but compounding only becomes clearly legal once a substance is added to the 503A bulks list through formal rulemaking after PCAC review. Regulatory attorneys caution that even on a smooth path, final rulemaking is likely more than a year away — though the FDA may announce interim enforcement discretion around the time of the PCAC meetings. Companies that own their compounding infrastructure can move the day that discretion lands. The contrast with the compounded GLP-1 era is deliberate: the FDA issued over eighty warning letters to telehealth companies for allegedly misleading marketing of compounded GLP-1 products in the twelve months ending March 2026. Vertical integration — owning the pharmacy, the prescriber network, and the patient relationship — is how platforms intend to stay on the right side of that enforcement line this time.
From Gray Market to Regulated Supply Chain
The structural story underneath these acquisitions is a supply chain migration. For three years, research peptides like BPC-157 and TB-500 moved primarily through 'research use only' gray-market channels with no potency verification, no sterility assurance, and no prescriber oversight. The HHS reclassification means these compounds will increasingly move through regulated channels — licensed compounding pharmacies, telehealth platforms, and supervised clinical settings — and that shift requires manufacturing, testing, and distribution infrastructure the gray market never built. New marketplace models connecting prescribers, 503A pharmacies, and patients are already emerging in anticipation. For consumers, the practical takeaway is that provenance is about to become the dividing line: peptides dispensed by a state-licensed 503A pharmacy under prescription will be categorically different products from unregulated vials sold online, even when the label names the same compound.
Eloralintide Enters Its Combination Era
On the pipeline side, attention after ADA 2026 (June 5–8, New Orleans) is consolidating around Eli Lilly's eloralintide (LY3841136), the selective amylin receptor agonist that posted 9.5%–20.1% weight loss versus 0.4% for placebo over 48 weeks in its Lancet-published Phase 2 — with a gastrointestinal tolerability profile notably milder than GLP-1 receptor agonists. Lilly is now running a dedicated Phase 2 trial of eloralintide alone and in combination with tirzepatide (NCT06916065), with analysts expecting combination data in late 2026, and Phase 3 monotherapy enrollment is slated to begin by the end of 2026. Analysts describe Lilly's strategy as treating amylin as a 'reusable building block': eloralintide validates the mechanism standalone, then pairs with tirzepatide today and potentially retatrutide tomorrow. With Novo Nordisk's CagriSema (cagrilintide + semaglutide) awaiting an October 2026 FDA decision and Zealand/Roche's petrelintide advancing, selective amylin agonism is now the most contested mechanism in obesity drug development.
What to Watch Next
Three timelines now run in parallel. Regulatory: public comments to FDA docket FDA-2025-N-6895 are due July 9, ahead of the PCAC's July 23–24 review of seven research peptides; a second PCAC meeting covering five more peptides (including GHK-Cu and Melanotan II) is expected by February 2027. Commercial: the Medicare GLP-1 Bridge launches July 1 at $50/month for Wegovy, Zepbound, and Foundayo, while telehealth platforms finish wiring their peptide supply chains. Pipeline: eloralintide + tirzepatide combination data late 2026, CagriSema's FDA decision in October, and retatrutide's NDA filing in Q4 2026. For the research peptide community, the next six weeks before PCAC are the most consequential since the 2023 restrictions — and the corporate maneuvering of June 2026 shows the industry is betting on a favorable outcome.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] MobiHealthNews — Noom acquires compounding pharmacy to expand beyond weight loss Source
- [2] Longevity.Technology — Noom buys pharmacy to push into healthy aging Source
- [3] InsideHealthPolicy — Telehealth Companies Jump Onto Peptides Amid Expected FDA Relief Source
- [4] FDA Law Blog — FDA's Pep(tide) Rally! What Compounders and Industry Need to Know Source
- [5] Fitt Insider — FDA Review Moves Peptides From Gray Market to Mainstream Source
- [6] BioSpace — Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026 Source
- [7] ClinicalTrials.gov — Eloralintide and Eloralintide With Tirzepatide (NCT06916065) Source
- [8] Eli Lilly — What to know about eloralintide Source
- [9] FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting Source
Related Articles
VANQUISH-2 Enrollment Complete, GLP1R GWAS Breakthrough, AI Peptide Design, and Hims & Hers Peptide Pivot: April 22, 2026 Update
Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment, a Nature GWAS identifies a GLP1R variant predicting drug response, CleaveNet AI designs tumor-targeted peptides, and Hims & Hers surges on FDA peptide review and Novo Nordisk settlement.
The close of ADA 2026 triggered a cluster of significant developments: Structure Therapeutics published the aleniglipron ACCESS Phase 2b results in Nature Medicine on June 5 — the first peer-reviewed full-data paper for an oral non-peptide GLP-1 RA in a major journal. Novo Nordisk announced that oral semaglutide (Wegovy pill) has surpassed 3 million prescriptions in five months. CVS Caremark announced a formulary reset that places Foundayo (orforglipron) and Zepbound on equal footing with Wegovy, reshaping the commercial GLP-1 landscape. And the FDA's Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to vote on whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP can be legally compounded — a pivotal regulatory moment for research peptides.
CMS's Medicare GLP-1 Bridge launches July 1, 2026, capping Wegovy, Zepbound, and Foundayo at $50/month for Medicare Part D beneficiaries — the most significant GLP-1 access expansion to date. We also track CagriSema's FDA review timeline, Eli Lilly's retatrutide NDA preparation for Q4 2026, and the approaching July 23–24 PCAC vote on BPC-157 and six other research peptides.